Advertisement
| cardiovascular drugs and therapy: Cardiac Drug Therapy M. Gabriel Khan, 2007-10-14 This book addresses the pharmacology and therapeutic application of drugs used to treat heart diseases and hypertension. Additions and updates to the sixth edition include six new chapters on current controversies in cardiac drug therapy such as the beta blocker issue many cardiologists are presently grappling with. The book provides practical advice on how to manage cardiac diseases and addresses the choice of one particular cardiac agent vs. another. |
| cardiovascular drugs and therapy: Current Cardiovascular Drugs William H. Frishman, Angela Cheng-Lai, Julie Chen, 2013-06-29 The third edition of Current Cardiovascular Drugs is designed to provide an updated practical compendium of current knowledge regarding cardiovascular drug therapy in a concise, easily readable format. The book is organized into chapters by drug class, and details the pharmacologic characteristics of specific treatment entities. The clinical efficacy and limitations of the various drug therapies are discussed using supportive reference material from the most authoritative sources and published clinical trials. |
| cardiovascular drugs and therapy: Symptoms in the Pharmacy Alison Blenkinsopp, Paul Paxton, John Blenkinsopp, 2013-03-27 A practical and evidence-based guide for student, pre-registration and qualified pharmacists Symptoms in the Pharmacy is an indispensable guide to the management of common symptoms seen in the pharmacy. With advice from an author team that includes both pharmacists and GPs, the book covers ailments which will be encountered in the pharmacy on a daily basis. Now in its sixth edition Symptoms in the Pharmacy has been fully revised to reflect the latest evidence and availability of new medicines. There are new sections and case studies for 'POM' to 'P' switches including chloramphenicol, sumatriptan, diclofenac, naproxen and amorolfine. This edition features colour photographs of skin conditions for the first time enabling the differentiation and diagnosis of common complaints. The public health and illness prevention content have been expanded to support this increasingly important aspect of the pharmacist’s work. The book is designed for quick and easy reference with separate chapters for each ailment. Each chapter incorporates a decision making framework in which the information necessary for treatment and suggestions on ‘when to refer’ is distilled into helpful summary boxes. At the end of each chapter there are example case studies providing the view of pharmacists, doctors and patients for most conditions covered. These easy-to-follow- chapters can be read cover to cover or turned to for quick reference. This useful guide should be kept close at hand for frequent consultation. |
| cardiovascular drugs and therapy: Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease Deepak L. Bhatt, Deepak L. Bhatt, MD, MPH, 2020-12 Authoritative, portable, and up to date, Opie's Cardiovascular Drugs, 9th Edition, is the definitive reference for quick access to frequently used drugs in all phases of care for cardiac patients. Now a part of the Braunwald family of renowned cardiology references, this compact title provides crucial information in an easily accessible format-ideal for cardiologists, residents, cardiology fellows, medical students, nurses, and other cardiac care providers. Updated to include the latest guidelines and evidence-based implications, it offers clear and concise explanations and pertinent clinical facts for all classes of cardiac drugs, as well as all the latest clinical trial results and evidence for the pharmacologic treatment of heart disease. Uses a new, consistent format for each drug class: overview and guidelines for use, mechanisms of action, differences among drugs in class, data for use, side effects, and drug interactions. Covers key topics such as new ESC and NLA guidelines, advances in lipid-lowering therapy, new diabetes drugs that improve cardiovascular outcomes, obesity drugs and cardiovascular and metabolic effects, drugs targeting inflammation, and combinations of antithrombotic therapies with analysis of risk-benefit. Provides guidance on how to effectively manage comorbid diseases. Contains dozens of unique Opiegram diagrams that demystify complex mechanisms of action and other drug processes-many updated to reflect current pathologic understanding of mechanisms. Enhanced eBook version included with purchase, which allows you to access all of the text, figures, and references from the book on a variety of devices |
| cardiovascular drugs and therapy: The ESC Handbook on Cardiovascular Pharmacotherapy Juan Carlos Kaski, Keld Per Kjeldsen, 2019 The ESC Handbook on Cardiovascular Pharmacotherapy, based on the most recent guidelines in cardiovascular pharmacology, and containing a comprehensive A-Z formulary of common and less commonly used cardiac drugs and drug groups, provides practical and accessible guidance on all areas of drug prescribing. |
| cardiovascular drugs and therapy: Cardiovascular Pharmacotherapeutics William H. Frishman, Domenic A. Sica, 2011 A critically acclaimed classic reference now in its third edition, Cardiovascular Pharmacotherapeutics provides current information regarding the contemporary use of all available cardiovascular medications for adults and children. Strongly emphasizing the scientific rationale behind the use of such therapies in cardiac disease, it discusses new drugs and novel compounds that are under development and may emerge as the cardiac therapies of the future. This edition also addresses special considerations for drug therapy use in the elderly, during pregnancy, and in those with hepatic or renal disease. A generous assortment of tables, figures, and appendices guides readers in their investigations of each drug group and various disease states. |
| cardiovascular drugs and therapy: Cardiovascular Drug Therapy , 1996 |
| cardiovascular drugs and therapy: Cardiovascular Therapeutics E-Book Elliott M. Antman, 2012-09-17 Manage cardiovascular problems more effectively with the most comprehensive resource available! A trusted companion to Braunwald's Heart Disease, Cardiovascular Therapeutics, 4th Edition addresses pharmacological, interventional, and surgical management approaches for each type of cardiovascular disease. This practical and clinically focused cardiology reference offers a balanced, complete approach to all of the usual and unusual areas of cardiovascular disease and specific therapies in one concise volume, equipping you to make the best choices for every patient. Consult this title on your favorite e-reader with intuitive search tools and adjustable font sizes. Elsevier eBooks provide instant portable access to your entire library, no matter what device you're using or where you're located. Understand current approaches to treating and managing cardiovascular patients for long-term health, for complex problems, and for unusual cardiac events. Benefit from the substantial experience of Elliott M. Antman, MD, Marc S. Sabatine, MD, and a host of other respected authorities, who provide practical, evidence-based rationales for all of today's clinical therapies. Expand your knowledge beyond pharmacologic interventions with complete coverage of the most effective interventional and device therapies being used today. Easily reference Braunwald's Heart Disease, 9th Edition for further information on topics of interest. Make the best use of the latest genetic and molecular therapies as well as advanced therapies for heart failure. Cut right to the answers you need with an enhanced focus on clinically relevant information and a decreased emphasis on pathophysiology. Stay current with ACC/AHA/ESC guidelines and the best ways to implement them in clinical practice. Get an enhanced visual perspective with an all-new, full-color design throughout. |
| cardiovascular drugs and therapy: Neonatal Cardiology Michael Artman, Lynn Mahoney, David F. Teitel, 2002-02-05 * Provides a sound background in the basic mechanisms of congenital heart disease * Includes guidelines for evaluating newborns with suspected heart disease * Offers advice on treatment and drug therapy guidelines |
| cardiovascular drugs and therapy: Cardiovascular Pharmacotherapeutics William H. Frishman, MD, Domenic A. Sica, MD, 2011-05-11 Everything practicing physicians and pharmacists need to know about drug therapy for cardiovascular disease. A critically acclaimed classic reference now in its third edition, Cardiovascular Pharmacotherapeutics provides current information regarding the contemporary use of all available cardiovascular medications for adults and children. Strongly emphasizing the scientific rationale behind the use of such therapies in cardiac disease, it discusses new drugs and novel compounds that are under development and may emerge as the cardiac therapies of the future. This edition also addresses special considerations for drug therapy use in the elderly, during pregnancy, and in those with hepatic or renal disease. A generous assortment of tables, figures, and appendices guides readers in their investigations of each drug group and various disease states. This new third edition presents an in-depth discussion of: All cardiovascular agents currently available The scientific basis behind every pharmacotherapy advance Mechanisms of action of cardiovascular pharmacotherapeutics The latest advances in cardiovascular drug therapy Specific drug treatments, and information on recently approved drugs Molecular biological advances Drugs in development Hands-on discussions of how to utilize specific drugs for treatment of various cardiovascular disorders and for the prevention of disease Also included are 8 appendices that provide practical, hands-on information on using drugs in clinical settings, including relevant pharmacokinetic information, and practical drug prescribing information. All updated with an accompanying website, Advances in Cardiovascular Pharmacotherapeutics www.cvpct3.com |
| cardiovascular drugs and therapy: Health in the European Union Philipa Mladovsky, 2009 Good health can be considered one of the most fundamental resources for social and economic prosperity. While the goal to improve average levels of population health is important, there has been an increasing focus on disparities at national and European levels. Improvements have been seen over the past few decades in both health status and living and working conditions has widened tremendously in the European Union (EU) and will continue to do so as it goes through the enlargement process. The diversity in living conditions has translated into diversity in patterns of health across the region. Inequalities in income, education, housing and employment affect population health, both directly (for example, good housing reduces risks associated with poor health) and indirectly through psychosocial factors (such as stress). From the life course perspective, individuals are affected by different sets of risks related to disease and illness; certain diseases and causes of health are more likely to affect young people, whereas the majority are associated with older ages. Investigating differences in health status within and between European countries provides the focus of this report. The relationship between living conditions, socioeconomic factors and health is discussed and analysed with the objective of stimulating a debate and policy action for creating a healthier and more equitable society. We aim to present an overview of key issues and not comprehensive literature review or exhaustive analysis of the topics involved. |
| cardiovascular drugs and therapy: Meyler's Side Effects of Cardiovascular Drugs Jeffrey K. Aronson, 2009-03-02 Elsevier now offers a series of derivative works based on the acclaimed Meylers Side Effect of Drugs, 15th Edition. These individual volumes are grouped by specialty to benefit the practicing physician or health care clinician. Each year, heart disease kills more people than cancer. Patients are treated by a variety of specialists and primary care practitioners, depending on the organ system involved. This volume enables practitioners to assess the adverse effects of the complete range of drugs used in cardiovascular medicine, including antihypertensive drugs, and drugs used in the treatment of heart failure, angina, angina pectoris, and cardiac arrhythmia and enable practitioners to prescribe preventative treatments with medications such as blood pressure reducers, aspirin, and cholesterol-lowering drugs, as well as drugs used for more aggressive therapy.The material is drawn from the 15th edition of the internationally renowned encyclopedia, Meyler's Side Effects of Drugs, and the latest volumes in the companion series, Side Effects of Drugs Annuals. Drug names have usually been designated by their recommended or proposed International Non-proprietary Names (rINN or pINN); when those are not available, clinical names have been used. In some cases, brand names have been used.This volume is critical for any health professional involved in the administration of cardiovascular mediations. - Surpasses the Physician's Desk Reference © by including clinical case studies and independent expert analysis - Complete index of drug names - Most complete cross referencing of drug-drug interactions available - Extensive references to primary and secondary literature - Also includes information on adverse effects in pregnancy The book is divided into six sections: - Drugs used to treat hypertension, heart failure and angina pectoris - Diuretics – a general introduction to their adverse effects, followed by monographs on individual drugs - Antidysrhythmic drugs - a general introduction to their adverse effects, followed by monographs on individual drugs - Drugs that act on the cerebral and peripheral circulations - Anticoagulants, thrombolytic agents, and anti-platelet drugs - Cardiovascular adverse effects of non-cardiovascular drugs |
| cardiovascular drugs and therapy: Oxford Desk Reference: Critical Care Carl Waldmann, 2008-11-27 The Oxford Desk Reference: Critical Care allows easy access to evidence-based materials on commonly encountered critical care problems for quick consultation to ensure the optimum management of a particular condition. A concise reference book, it collates key recommendations and presents them in an easily accessible and uniform way. |
| cardiovascular drugs and therapy: Pathophysiology and Pharmacotherapy of Cardiovascular Disease Gowraganahalli Jagadeesh, Pitchai Balakumar, Khin Maung-U, 2015-05-06 The present book covers the basic principles of cardiovascular physiology, pathophysiology and advanced pharmacology with particular emphasis on cellular mechanisms of drug action. It provides an update on the progress made in several aspects of cardiovascular diseases so that it might kindle scientists and clinicians alike in furthering basic and translational research. In addition, the book is expected to fill imperative gaps in understanding and optimally treating cardiovascular disease. |
| cardiovascular drugs and therapy: Cardiac Problems in Pregnancy Uri Elkayam, 2019-09-02 Cardiac Problems in Pregnancy offers clinicians the most detailed and comprehensive guide to diagnosing and managing pregnancy-associated cardiovascular diseases currently available. Covering a wide spectrum of congenital and acquired cardiovascular conditions, its extensive contents examine diseases of the heart with an expert awareness of the implications of pregnancy and the attendant physiological changes it brings. Such guidance is vitally required in an age in which congenital and acquired heart diseases are the leading causes of non-obstetrical maternal morbidity and mortality. Featuring 36 new or extensively revised chapters, this fourth edition of the book complements coverage of the latest research and clinical advances with a complete and up-to-date bibliography of literature on pregnancy in women with cardiovascular conditions. It also serves as a practical, step-by-step companion for those caring for heart disease patients during pregnancy, labor, and the post-partum period. Contents include: Coverage of all elements of maternal cardiology Newly written chapters featuring fresh research and data Guidance on performing risk assessments and interventions both prior to and during gestation Explanations of a range of diagnostic and therapeutic approaches to cardiovascular disease in pregnant patients Drawing on expertise from across the fields of cardiovascular medicine, obstetrics, anesthesiology, cardiac surgery, pharmacology, and clinical science, Cardiac Problems in Pregnancy is designed to give invaluable support to all medical professionals involved in maximizing the safety and success of cardiologically complex pregnancies. |
| cardiovascular drugs and therapy: Cardiac Drugs Made Ridiculously Simple Michael A. Chizner, Ryan E. Chizner, 2023-05-15 |
| cardiovascular drugs and therapy: Cardiovascular Drug Therapy Adam Schneeweiss, 2012-12-06 The· first meeting of the cardiovascular drug therapy forum took place on April 13-15, 1988 in Montreux, Switzerland. In this meeting, which was closed to the public, approximately 150 leading investigators in the field of cardiovascular drug therapy, both academics and from the pharmaceutical industry, discussed the state of the art and future trends of this rapidly expanding field. The discussions concentrated on four major topics: (1) ischemic heart disease; (2) heart failure; (3) hyper tension; (4) arrhythmias. These topics were discussed by four committees in parallel, and thereafter the main points were reviewed by the whole forum. This framework allowed both intensive and interdisciplinary discussions. This book, the first publication of selected topics from the meeting, focuses mainly on nitrate therapy in ischemic heart disease and heart failure. Adam Schneeweiss, MD Chairman v Contents Opening Remarks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Presentation of the Sir Thomas Lauder Brunton Award for Outstanding Nitrate Research . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Origins of Symptoms in Heart Failure - Relevance in Evaluation of New Drugs . . . . . . . . . . . . . . . . . . . . 5 Mononitrates in Congestive Heart Failure . . . . . . . . . . . . . . . . . 9 Are There Differences Between the Various Formulations of Nitrates in Heart Failure? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Long-Term Nitrate Therapy - A Decade of Changing Concepts . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Nitrate Therapy in Angina Pectoris . . . . . . . . . . . . . . . . . . . . . . . . 23 Mononitrates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 Transdermal Administration of Nitrates . . . . . . . . . . . . . . . . . . . 53 Nitrates in Angina Pectoris - Rationale of Use and Avoidance of Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67 Treatment of Congestive Heart Failure - Summary . . . . . . . . |
| cardiovascular drugs and therapy: Frontiers in Cardiovascular Drug Discovery Atta-ur-Rahman, M. Iqbal Choudhary, 2016-11-01 Frontiers in Cardiovascular Drug Discovery is an eBook series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The eBook series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology. The third volume of the series covers the following topics: - P2Y12 receptor agonists -Heart failure pharmacotherapy -Vasopressin and the cardiovascular system -Cerebral small vessel disease -Complement blocking therapeutic strategies -New antiplatelet and anticoagulating agents for gastrointestinal treatments |
| cardiovascular drugs and therapy: Statin-Associated Muscle Symptoms Paul D. Thompson, Beth A. Taylor, 2020-01-25 This book provides an overview of statin-associated muscle symptoms (SAMS) from clinical presentation to treatment and possible metabolic causes. It examines the risk factors, presentations, diagnosis and differential diagnosis, clinical management, and financial costs of SAMS. The book also highlights patients’ perspectives on SAMS such as the psychosocial, emotional, and societal factors influencing their perceptions and experiences. Finally, the book presents the results of observational and clinical trials on the prevalence of SAMS, clinical trials for treatments, and potential future research approaches for improving the understanding and treatment of SAMS. A key addition to the Contemporary Cardiology series, Statin-Associated Muscle Symptoms is an essential resource for physicians, medical students, residents, fellows, and allied health professionals in cardiology, endocrinology, pharmacotherapy, primary care, and health promotion and disease prevention. |
| cardiovascular drugs and therapy: Antiarrhythmic Drugs Antoni Martínez-Rubio, Juan Tamargo, Gheorghe- Andrei Dan, 2020-02-03 This volume reviews current and potential future therapies for arrhythmias. It is a highly practical guide for the use of pharmaceuticals in the management of the discipline, and has been written in a simple quick-access format. Antiarrhythmic Drugs builds on the current understanding of pathophysiological mechanisms and insights gained from previous studies of therapeutic interventions. It is designed to establish the baseline level of knowledge that a cardiovascular professional needs to know on a day-to-day basis. |
| cardiovascular drugs and therapy: Emergency Cardiovascular Pharmacotherapy Barbara S. Wiggins, Cynthia A. Sanoski, 2012-01-01 Take control of life-or-death situations with Emergency Cardiosvascular Pharmacotherapy: A Point-Of-Care Guide. The latest portable, authoritative resource from ASHP closes the gap with immediate, life-saving information that pharmacists, students, residents and other health care practitioners need, all in one place. Illustrative tables, figures and bullets provide critical information, instantly. Learn the role of each member of the code team, especially pharmacists. Understand how to read, interpret and respond to an electrocardiogram. Explore routes of emergency drug administration, including how and when. Clinical pearls highlight the administration of specific drugs. Go in-depth with an entire chapter devoted to treatment algorithms. In the classroom or clinic, no other guide provides such detailed, evidence-based focus on the pharmacologic agents used to manage the entire range of life-threatening cardiovascular conditions. Authored by national experts in cardiovascular pharmacotherapy, all 10 chapters meet the latest national guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. |
| cardiovascular drugs and therapy: Disease Control Priorities, Third Edition (Volume 5) Dorairaj Prabhakaran, Shuchi Anand, Thomas A. Gaziano, Jean-Claude Mbanya, Rachel Nugent, 2017-11-17 Cardiovascular, respiratory, and related conditions cause more than 40 percent of all deaths globally, and their substantial burden is rising, particularly in low- and middle-income countries (LMICs). Their burden extends well beyond health effects to include significant economic and societal consequences. Most of these conditions are related, share risk factors, and have common control measures at the clinical, population, and policy levels. Lives can be extended and improved when these diseases are prevented, detected, and managed. This volume summarizes current knowledge and presents evidence-based interventions that are effective, cost-effective, and scalable in LMICs. |
| cardiovascular drugs and therapy: The ESC Textbook of Preventive Cardiology Stephan Gielen, Guy De Backer, Massimo Piepoli, David Wood, 2015 EACPR, European Association for Cardiovascular Prevention and Rehabilitation -- European Society of Cardiology. |
| cardiovascular drugs and therapy: Cardiac Pharmacology R. Douglas Wilkerson, 2013-10-22 Cardiac Pharmacology aims to interface basic and clinical knowledge of those interventions used or being studied for use in the treatment of heart disease. The book is divided into four major sections which address intrinsic and neural control of cardiac function, pharmacologic modification of cardiac contractility and cardiac output, the genesis and control of cardiac arrhythmias, and pharmacologic manipulation of myocardial oxygen supply and demand. The last three sections contain a chapter describing the techniques employed in the study of that particular aspect of cardiac function and its alterations by pharmacologic interventions. Cardiologists, pharmacologists, physiologists, and those interested in the area of cardiovascular medicine will find the book insightful. |
| cardiovascular drugs and therapy: Cardiac Drug Therapy M. I. Gabriel Khan, 1995 Features a rationale for the choice of drug in given clinical situations and how best to manage cardiac problems. The format summarizes how the drug is supplied, dosage guidelines, action pharmacokinetics, clinical advice, efficacy, adverse effects, contraindications and interactions. |
| cardiovascular drugs and therapy: Applications of Biotechnology in Cardiovascular Therapeutics Kewal K. Jain, 2011-07-25 For physicians, surgeons, and scientists working on cardiovascular disorders, Applications of Biotechnology in Cardiovascular Therapeutics serves as an invaluable reference by collecting the essential writings of Dr. Kewal K. Jain on the topics of biotechnology as they relate to cardiovascular disease. This thorough volume includes such subjects as biotechnology and therapeutic delivery to the cardiovascular system, cell-selective targeted drug delivery, cell and gene therapies, including antisense and RNA interference, cutting-edge gene therapy approaches, as well as personalized cardiology as a way of integrating new technologies into the selection of the best possible treatment for an individual patient. Selected references from recent literature are collected for each chapter, and the text is supplemented by a variety of useful tables and figures. Comprehensive and up-to-date, Applications of Biotechnology in Cardiovascular Therapeutics will be tremendously useful for those working in life sciences and the pharmaceutical sciences, and the inclusion of some basics of cardiovascular diseases will greatly benefit nonmedical readers as well. |
| cardiovascular drugs and therapy: Drugs for the Heart Lionel H. Opie, Bernard J. Gersh, 2005 The new 6th Edition continues to be the definitive pocket-sized guide on the hows and whys of cardiovascular drugs. It provides in-depth information on all of the drug classes used to treat heart disease, and covers drug use, new drug classes, drug use for single and multiple problem management, and more. A user-friendly organization speed readers to the information they need, and dynamic new full-color drawings illustrate key pharmacological and physiological actions. The new edition includes access to the companion website, which offers bi-annual content updates to keep you current with new drugs, indications and leading trials. The website also has the feature of fully searchable text to access book content via drug, disease or drug action. |
| cardiovascular drugs and therapy: Cardiovascular Drug Therapy in the Elderly Adam Schneeweiss, Gotthard Schettler, 2014-01-15 |
| cardiovascular drugs and therapy: Cardiovascular Drugs and the Management of Heart Disease Gordon A. Ewy, Rubin Bressler, 1992 A revised and updated second edition of this clinical reference text, providing information on the clinical pharmacology, clinical indications, use, and relative costs of all cardiac and cardiovascular drugs available in 1991. |
| cardiovascular drugs and therapy: Antiplatelet and Anticoagulation Therapy Albert Ferro, David A. Garcia, 2012-10-13 This title will be presented as highly practical information pn pharmaceutical antiplatelet and anticoagulation therapy, written in a quick-access, no-nonsense format. The emphasis will be on a just-the-facts clinical approach, heavy on tabular material, light on dense prose. The involvement of the ISCP will ensure that the best quality contributors will be involved and establish a consistent approach to each topic in the series. Each volume is designed to be between 120 and 250 pages containing practical illustrations and designed to improve understand and practical usage of cardiovascular drugs in specific clinical areas. |
| cardiovascular drugs and therapy: Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-oncology Imteyaz Qamar, Pawan Kumar Maurya, 2022-05-26 Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyzes the emerging the field of cardio-oncology, reviewing recent advancements in the field, discussing how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms and concepts, which is followed by advanced state-of-art of cardio-oncology. Other sections cover tyrosine kinase inhibitors, Anthracyclines, and biomarkers in cardiotoxicity induced by chemotherapeutic drugs, noninvasive cardiovascular imaging techniques, radiotherapy induced cardiovascular, and more. Anti-cancer treatment is associated with serious cardiovascular adverse events, including arterial and pulmonary hypertension, supraventricular and ventricular arrhythmias, systolic and diastolic cardiac dysfunction and coronary artery disease. Progress in cancer therapy over the past decades improved long-term survival but increased cancer therapy-related cardiotoxicity. Both traditional chemotherapeutic agents and newer therapies have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications—arrhythmias, heart failure, and even death. - Adopts a translational approach and comprehensively covers the basic science, mechanisms and concepts of cardio-oncology - Outlines the current knowledge of biomarkers in cancer therapy-related cardiotoxicity - Provides an understanding of the mechanisms of cardiovascular toxicity of various therapies that may lead to the identification of novel targets to reduce vascular complications |
| cardiovascular drugs and therapy: Pharmacological Treatment of Chronic Stable Angina Pectoris Pablo Avanzas, Juan Carlos Kaski, 2015-06-02 This book is intended for general cardiologists and other physicians involved in the care of patients with chronic stable angina (CSA). The goal of this book is to update clinicians on recent data on the medical management of patients with CSA. Ischemic heart disease remains a major public health problem. Chronic stable angina is the initial manifestation of ischemic heart disease in approximately one half of patients. Stable coronary artery disease is generally characterized by episodes of reversible myocardial demand/supply mismatch, related to ischaemia or hypoxia, which are usually inducible by exercise, emotion or other stress and reproducible—but, which may also be occurring spontaneously. Such episodes of ischaemia/hypoxia are commonly associated with transient chest discomfort (angina pectoris). The aim of the management of CSA is to reduce symptoms and improve prognosis. The management of these patients encompasses lifestyle modification, control of coronary artery disease risk factors, evidence-based pharmacological therapy and patient education. All patients with stable angina should be offered optimal medical treatment, defined as one or two anti-anginal drugs as necessary, plus drugs for secondary prevention of cardiovascular disease. Regarding the role of revascularization, randomised trials provide compelling evidence that myocardial revascularisation by coronary artery bypass grafting or by percutaneous coronary intervention improves symptoms of angina relative to continued medical treatment. |
| cardiovascular drugs and therapy: Cardiovascular Diseases Y. Robert Li, 2015-04-06 Written in an accessible style and consistent format, the book covers both the fundamentals and advances in the pharmacology of cardiovascular drugs, as well as their integrated applications in the management of individual cardiovascular diseases. • Integrates fundamentals and recent advances regarding cardiovascular drugs, blending basic and clinical sciences needed to effectively understand and treat cardiovascular diseases • Facilitates understanding of drug action and mechanism by covering physiology / pathophysiology and pharmacology • Includes guidelines and algorithms for pharmacotherapeutic management of cardiovascular diseases • Uses case presentations and study questions to enhance understanding of the material • Serves as a resource for pharmaceutical and medical students and researchers interested in cardiovascular issues |
| cardiovascular drugs and therapy: Cardiovascular Pharmacotherapeutics Manual William H. Frishman, Edmund H. Sonnenblick, Domenic A. Sica, 2003-11-13 This manual, based on the definitive reference, is a concise and portable guide to the pharmacologic management of cardiovascular conditions. Focused on clinically relevant information related to drug treatment, this book features tables and charts for quick reference. |
| cardiovascular drugs and therapy: Heart and Toxins Dr. Meenakshisundaram Sundaram Ramachandran, 2014-08-12 The Heart and Toxins brings together global experts to provide the latest information and clinical trials that make the connection between genetic susceptibility, gene expression, and environmental factors in cardiovascular diseases. This unique reference, edited by renowned cardiologist Meenakshi Sundaram Ramachandran, solves the problem of managing multiple clinical cases of cardiovascular toxicity. It allows connections to be made between research, diagnosis, and treatment to avoid higher morbidity and mortality rates as a result of cardiovascular toxicity. - Structured to bring together exploration into the epidemiology, molecular mechanism, pathogenesis, environmental factors and management in cardiovascular toxins - Included various topics on cardiovascular toxins such as plant, chemical, animal, nanomaterial and marine biology induced cardiac damage – which are new ideas discussed in detail - Comprehensive chapters on the cardiovascular toxicity from drugs, radiotherapy and radiological imaging - Enables you to manage multiple clinical cases of cardiovascular toxicity - Outlined conclusions at the end of each chapter providing key learning points to help you organize the chapter's details without losing insight |
| cardiovascular drugs and therapy: Fundamentals of Anaesthesia Colin Pinnock, Ted Lin, Robert Jones, Tim Smith, 2002-12 The second edition of Fundamentals of Anaesthesia builds upon the success of the first edition, and encapsulates the modern practice of anaesthesia in a single volume. Written and edited by a team of expert contributors, it provides a comprehensive but easily readable account of all of the information required by the FRCA Primary examination candidate and has been expanded to include more detail on all topics and to include new topics now covered in the examination. As with the previous edition, presentation of information is clear and concise, with the use of lists, tables, summary boxes and line illustrations where necessary to highlight important information and aid the understanding of complex topics. Great care has been taken to ensure an unrivalled consistency of style and presentation throughout. |
| cardiovascular drugs and therapy: Cardiovascular and Pulmonary Physical Therapy, Second Edition Lawrence P Cahalin, William E. DeTurk, 2010-12-22 A comprehensive textbook spanning the entire scope of cardiovascular and pulmonary practice Includes CD-ROM with interactive case studies Cardiovascular and Pulmonary Physical Therapy reflects the broadest possible spectrum of cardiovascular and pulmonary practice and draws upon the expertise of more than two dozen internationally recognized contributors. The second edition has been updated to cover the sweeping changes that have occurred in both the practice of physical therapy and the education of physical therapy students. These changes include health care cost containment, the introduction of the Guide to Physical Therapist Practice, and the utilization of the disablement model. Features: The Guide to Physical Therapy Practice is integrated throughout with an entire chapter devoted to its history and use Preferred practice patterns for cardiovascular and pulmonary physical therapy form the core of eight chapters are used as springboards to describe interventions and outcomes Case studies in practice pattern chapters allows readers to experience the proper application of the practice patterns The patient-client management model is used in the case studies with appropriate test, measures, and interventions selected from the practice patterns and applied to the patient “International Perspectives” provide a way to gain insight into the global practice of physical therapy Evidence-based and peer reviewed published material is included to help readers develop specific intervention regimens Companion CD-ROM includes case-study-based exercises, video clips illustrating technical psychomotor skills, and demonstrations of cardiac and pulmonary physical exams |
| cardiovascular drugs and therapy: The ESC Textbook of Cardiovascular Medicine European Society of Cardiology, 2009-08-27 Following the structure and format of the ESC core syllabus, this text introduces key concepts in the field of cardiovascular medicine. |
| cardiovascular drugs and therapy: Experimental Stress Analysis for Materials and Structures Alessandro Freddi, Giorgio Olmi, Luca Cristofolini, 2015-03-19 This book summarizes the main methods of experimental stress analysis and examines their application to various states of stress of major technical interest, highlighting aspects not always covered in the classic literature. It is explained how experimental stress analysis assists in the verification and completion of analytical and numerical models, the development of phenomenological theories, the measurement and control of system parameters under operating conditions, and identification of causes of failure or malfunction. Cases addressed include measurement of the state of stress in models, measurement of actual loads on structures, verification of stress states in circumstances of complex numerical modeling, assessment of stress-related material damage, and reliability analysis of artifacts (e.g. prostheses) that interact with biological systems. The book will serve graduate students and professionals as a valuable tool for finding solutions when analytical solutions do not exist. |
| cardiovascular drugs and therapy: Handbook of Pediatric Cardiovascular Drugs Ricardo Munoz, Eduardo M. da Cruz, Carol G. Vetterly, David S. Cooper, Donald Berry, 2014-06-26 A Second Edition of this handbook of drugs used in pediatric cardiac care will satisfy the need for a quick up-to-date reference source of common drug therapy. There are no major texts available in the field of pediatric cardiology that exclusively provide therapeutic drug information. Several sources are available that present drug information for cardiology, but these place no emphasis on pediatric care and are written for general cardiac specialists. |
Cardiovascular diseases (CVDs) - World Health Organization (WHO)
Jun 11, 2021 · Cardiovascular diseases (CVDs) are the leading cause of death globally. An estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. …
Cardiovascular diseases - World Health Organization (WHO)
Jul 17, 2024 · Cardiovascular diseases (CVDs) are the leading cause of death and disability in the WHO European Region. An estimated 4.2 million people in Europe died from CVDs in 2019, …
Cardiovascular diseases - World Health Organization (WHO)
Mar 21, 2017 · Cardiovascular diseases CVDs are a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease …
心血管疾病 - World Health Organization (WHO)
Jun 11, 2021 · WHO cardiovascular diseases fact sheet providing key facts and information on risk factors, symptoms, rheumatic heart disease, treatment and prevention, WHO response.
Cardiovascular diseases kill 10 000 people in the WHO European …
Copenhagen, Denmark, 15 May 2024 Most people in the WHO European Region consume far too much salt, and more than one in three adults aged 30–79 has hypertension, the medical term …
心血管疾病 - World Health Organization (WHO)
心血管疾病是全球一大死亡原因，估计每年夺走1790万人的生命。心血管疾病是心脏和血管疾病的一个类别，包括冠心病、脑血管病、风湿性心脏病和其他疾病。
Cardiovascular diseases (CVD) in Viet Nam - World Health …
Mar 15, 2017 · Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. CVDs are a group of disorders of the heart and blood …
DOH, WHO scale up efforts to prevent cardiovascular diseases in …
Jun 21, 2023 · The Department of Health (DOH) and the World Health Organization (WHO) expanded the reach of the Healthy Hearts Programme in Western Visayas to intensify efforts …
WHO updates Cardiovascular Risk Charts
Sep 2, 2019 · WHO has updated the cardiovascular risk charts through the WHO Cardiovascular disease risk chart working group. Updated charts are published today in the Lancet Global …
Prevention of cardiovascular disease : guidelines for assessment …
Jan 1, 2007 · Cardiovascular disease is a major cause of disability and premature death throughout the world, and contributes substantially to the escalating costs of health care. The …
Cardiovascular diseases (CVDs) - World Health Organi…
Jun 11, 2021 · Cardiovascular diseases (CVDs) are the leading cause of death globally. An estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. …
Cardiovascular diseases - World Health Organization (W…
Jul 17, 2024 · Cardiovascular diseases (CVDs) are the leading cause of death and disability in the WHO European Region. An estimated 4.2 million people in Europe died from CVDs in 2019, …
Cardiovascular diseases - World Health Organization (W…
Mar 21, 2017 · Cardiovascular diseases CVDs are a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease and …
心血管疾病 - World Health Organization (WHO)
Jun 11, 2021 · WHO cardiovascular diseases fact sheet providing key facts and information on risk factors, symptoms, rheumatic heart disease, treatment and prevention, WHO …
Cardiovascular diseases kill 10 000 people in the WHO Europ…
Copenhagen, Denmark, 15 May 2024 Most people in the WHO European Region consume far too much salt, and more than one in three adults aged 30–79 has hypertension, the medical …
